Zhonghua Wang

2.1k total citations
57 papers, 1.3k citations indexed

About

Zhonghua Wang is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhonghua Wang has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 20 papers in Cancer Research and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhonghua Wang's work include Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (16 papers) and Breast Cancer Treatment Studies (12 papers). Zhonghua Wang is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (16 papers) and Breast Cancer Treatment Studies (12 papers). Zhonghua Wang collaborates with scholars based in China, Canada and United States. Zhonghua Wang's co-authors include Biyun Wang, Xichun Hu, Jian Zhang, Jun Cao, Zhongsheng Tong, Michał M. Masternak, Leiping Wang, A. Bartke, Khalid Al-Regaiey and Si Sun and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Zhonghua Wang

53 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhonghua Wang China 20 683 415 409 265 114 57 1.3k
Michela Roberto Italy 19 598 0.9× 294 0.7× 343 0.8× 166 0.6× 86 0.8× 75 1.1k
Mi Ran Yun South Korea 22 558 0.8× 622 1.5× 483 1.2× 268 1.0× 86 0.8× 49 1.4k
Shingo Sakashita Japan 23 439 0.6× 639 1.5× 392 1.0× 290 1.1× 94 0.8× 104 1.4k
Georg Pfeiler Austria 24 952 1.4× 532 1.3× 286 0.7× 527 2.0× 93 0.8× 91 1.7k
Laura García‐Estévez Spain 20 1.1k 1.5× 438 1.1× 506 1.2× 649 2.4× 121 1.1× 68 1.7k
Yahya Elshimali United States 20 494 0.7× 703 1.7× 348 0.9× 498 1.9× 108 0.9× 36 1.4k
Jun Cao China 23 562 0.8× 810 2.0× 336 0.8× 418 1.6× 82 0.7× 74 1.6k
Kelly M. Quesnelle United States 17 393 0.6× 574 1.4× 207 0.5× 154 0.6× 162 1.4× 35 1.2k
Tao Sun China 19 672 1.0× 379 0.9× 451 1.1× 185 0.7× 45 0.4× 92 1.4k

Countries citing papers authored by Zhonghua Wang

Since Specialization
Citations

This map shows the geographic impact of Zhonghua Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhonghua Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhonghua Wang more than expected).

Fields of papers citing papers by Zhonghua Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhonghua Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhonghua Wang. The network helps show where Zhonghua Wang may publish in the future.

Co-authorship network of co-authors of Zhonghua Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhonghua Wang. A scholar is included among the top collaborators of Zhonghua Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhonghua Wang. Zhonghua Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jin, Xi, Yin Liu, Zi-Yu Wang, et al.. (2025). Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nature Medicine. 31(7). 2405–2415. 3 indexed citations
2.
3.
Bai, Qianming, Ming Li, Shuling Zhou, et al.. (2024). Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns. Journal of Clinical Pathology. 78(8). 540–547. 3 indexed citations
4.
5.
Zhou, Changdong, G. Chen, Yunchao Huang, et al.. (2024). 61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study. ESMO Open. 9. 102640–102640. 1 indexed citations
6.
7.
Shao, Zhimin, Lei Fan, Song‐Yang Wu, et al.. (2023). FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3011–3011. 2 indexed citations
8.
Liu, Yin, Lei Fan, Zhonghua Wang, & Zhi‐Ming Shao. (2022). Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. The Oncologist. 28(1). 86–e76. 6 indexed citations
9.
Wang, Zhonghua, Junyan Lyu, Wenhao Luo, & Xiaoying Tang. (2022). Superpixel Inpainting For Self-Supervised Skin Lesion Segmentation from Dermoscopic Images. 2022 IEEE 19th International Symposium on Biomedical Imaging (ISBI). 1–4. 6 indexed citations
10.
Ji, Lei, et al.. (2021). Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer. 21(1). 238–238. 40 indexed citations
11.
12.
Zuo, Wen‐Jia, Min He, Hui Zheng, et al.. (2021). Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. Gland Surgery. 10(4). 1300–1314. 7 indexed citations
13.
Li, Zhang, Jia Ding, Huiyan Li, Zhonghua Wang, & Jian Wu. (2020). Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1874(2). 188441–188441. 61 indexed citations
14.
Wang, Zhonghua, et al.. (2019). In situ metabolomics in nephrotoxicity of aristolochic acids based on air flow-assisted desorption electrospray ionization mass spectrometry imaging. Acta Pharmaceutica Sinica B. 10(6). 1083–1093. 67 indexed citations
15.
Liu, Rujiao, Jun Cao, Xiang Gao, et al.. (2016). Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumor Biology. 37(10). 14083–14088. 49 indexed citations
16.
Li, Ting, Biyun Wang, Zhonghua Wang, et al.. (2015). Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS ONE. 10(7). e0133133–e0133133. 6 indexed citations
17.
Hu, Xichun, Biyun Wang, Jian Zhang, et al.. (2014). Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. International Journal of Nanomedicine. 9. 1443–1443. 19 indexed citations
18.
Wu, Chuntao, et al.. (2013). Effect of spironolactone on cardiac remodeling after acute myocardial infarction. World Journal of Emergency Medicine. 4(1). 48–48. 12 indexed citations
19.
Qiu, Li‐Xin, Xiaodong Zhu, Chunlei Zheng, et al.. (2010). The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects. Breast Cancer Research and Treatment. 124(2). 475–479. 16 indexed citations
20.
Königsberger, Erich, Zhonghua Wang, & Lan-Chi Königsberger. (2000). Solubility of L-Cystine in NaCl and Artificial Urine Solutions. Monatshefte für Chemie - Chemical Monthly. 131(1). 39–45. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michela Roberto Breakdown of academic impact, for papers by Mi Ran Yun Breakdown of academic impact, for papers by Shingo Sakashita Breakdown of academic impact, for papers by Georg Pfeiler Breakdown of academic impact, for papers by Laura García‐Estévez Breakdown of academic impact, for papers by Yahya Elshimali Breakdown of academic impact, for papers by Jun Cao Breakdown of academic impact, for papers by Kelly M. Quesnelle Breakdown of academic impact, for papers by Tao Sun
Rankless by CCL
2026